サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1760940

人工多能性幹細胞（iPSC）の世界市場

Induced Pluripotent Stem Cell (iPSC)

出版日
ページ情報
英文 349 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.89円
人工多能性幹細胞（iPSC）の世界市場
出版日: 2025年07月02日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 349 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

人工多能性幹細胞（iPSC）の世界市場は2030年までに32億米ドルに到達

2024年に21億米ドルと推定される人工多能性幹細胞（iPSC）の世界市場は、2024年から2030年にかけてCAGR 7.0%で成長し、2030年には32億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである血管細胞は、CAGR7.5%を記録し、分析期間終了時には11億米ドルに達すると予測されます。心臓細胞セグメントの成長率は、分析期間でCAGR 8.2％と推定されます。

米国市場は9億3,770万米ドルと推定、中国はCAGR 8.9％で成長予測

米国の人工多能性幹細胞（iPSC）市場は、2024年に9億3,770万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億1,680万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.8％と7.2％と予測されています。欧州では、ドイツがCAGR約6.7%で成長すると予測されています。

世界の人工多能性幹細胞（iPSC）市場- 主要動向と促進要因まとめ

人工多能性幹細胞（iPSC）とは何か？

人工多能性幹細胞（iPSC）は、成体細胞から直接作製できる幹細胞の一種です。iPSC技術は2006年に山中伸弥氏によって開拓され、転写因子をコードする4つの特定の遺伝子を導入することで、成体細胞を多能性幹細胞に変えることができることを実証しました。これらの細胞は、胚性幹細胞と同様に、ヒトの体内でほぼすべての種類の細胞に成長する能力を持つが、胚を使用する必要がないため、倫理的な問題はないです。この画期的な発見により、再生医療、創薬、疾患モデリングの分野に新たな道が開かれました。iPS細胞は、脊髄損傷からパーキンソン病まで、さまざまな疾患の治療に患者自身から採取した細胞を使用できる、患者特異的治療の開発に特に有望であり、個別化医療に革命をもたらす可能性があります。

iPS細胞はどのように医学研究と治療に革命をもたらすのか？

iPS細胞はその多用途性から、医学研究と治療の分野で貴重なツールとなっています。特定の遺伝子疾患を持つ患者の細胞を再プログラムすることで、科学者は同じ遺伝子異常を持つiPS細胞を作成することができます。これらのiPS細胞は、病気の病態を細胞レベルで研究するために使用することができ、他のタイプの細胞では不可能な洞察を得ることができます。例えば、iPS細胞はALS、糖尿病、アルツハイマー病などの疾患モデルに使用されており、研究者は疾患メカニズムを理解し、潜在的な創薬標的を発見することができます。さらに、薬物試験の分野では、ヒトで試験する前に新薬の有効性と安全性を評価するためにiPSCを使用することができ、動物実験への依存を減らし、薬物反応の予測可能性を向上させることができます。こうした応用は、複雑な疾患に対する理解を深めるだけでなく、より効果的で安全な治療への道を開きます。

どのような技術の進歩がiPSC調査を推進しているのか？

遺伝子編集と組織工学の進歩がiPSCの調査と応用を推進しています。CRISPR/Cas9技術とiPSC技術の統合により、遺伝子レベルでの正確な改変が可能になり、治療開発や疾患モデリングにおけるiPSCの可能性が高まっています。研究者は現在、患者由来のiPS細胞の遺伝的欠陥を修正することができ、遺伝性疾患を治癒する細胞治療ソリューションにつながる可能性があります。さらに、3Dバイオプリンティング技術の開発により、iPSCから複雑な組織を作ることができるようになりました。これらの技術革新は、細胞の初期化の効率や分化した細胞の成熟度など、iPS細胞研究における現在の限界を克服し、これらの細胞をより臨床応用可能なものにするために極めて重要です。

iPSC市場急拡大の原動力は？

iPSC市場の成長は、生物医学研究の著しい進歩や個別化医療の重視の高まりなど、いくつかの要因によって牽引されています。治療や研究に患者特異的な細胞を提供するiPSCの可能性は、官民双方からの多額の投資につながっています。損傷した細胞、組織、臓器を置き換えることで、正常な機能を回復または確立しようとする再生医療の拡大は、iPSC技術の革新に大きく依存しています。さらに、慢性疾患や遺伝性疾患の蔓延が拡大していることから、iPSCが実現しうる新たな治療戦略に対する需要が高まっています。加えて、胚性幹細胞に比べてiPSCが規制当局から支持され、倫理的に受け入れられていることも、この技術のさらなる開発と応用を後押ししています。これらの促進要因が相まって、ダイナミックで急速に進展する市場が形成され、今後数年間でヘルスケアと治療のパラダイムに革命をもたらすことが期待されます。

セグメント

細胞タイプ（血管細胞、心臓細胞、神経細胞、肝細胞、免疫細胞、その他の細胞タイプ）、調査方法（細胞リプログラミング、細胞培養、細胞分化、細胞分析、細胞工学、その他の調査方法）、用途（医薬品開発・毒性試験、学術研究、再生医療、その他の用途）

調査対象企業の例（注目の51社）

  • Lonza Group Ltd.
  • Evotec SE
  • FUJIFILM Holdings Corporation
  • Abcam PLC
  • Horizon Discovery Ltd.
  • Cell Signaling Technology, Inc.
  • Cell Applications, Inc.
  • Invivogen
  • ALSTEM, LLC
  • Censo Biotechnologies Ltd.
  • Creative Bioarray
  • Creative Biolabs
  • Axol Bioscience Ltd.
  • ID Pharma Co., Ltd.
  • BlueRock Therapeutics, LLC

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオトランスクリプト、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中のドメインエキスパートからキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP12568

Global Induced Pluripotent Stem Cell (iPSC) Market to Reach US$3.2 Billion by 2030

The global market for Induced Pluripotent Stem Cell (iPSC) estimated at US$2.1 Billion in the year 2024, is expected to reach US$3.2 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Vascular Cells, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Cardiac Cells segment is estimated at 8.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$937.7 Million While China is Forecast to Grow at 8.9% CAGR

The Induced Pluripotent Stem Cell (iPSC) market in the U.S. is estimated at US$937.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$116.8 Million by the year 2030 trailing a CAGR of 8.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.8% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.7% CAGR.

Global Induced Pluripotent Stem Cell (iPSC) Market - Key Trends & Drivers Summarized

What Are Induced Pluripotent Stem Cells (iPSCs) and Their Breakthrough Potential?

Induced pluripotent stem cells (iPSCs) are a type of stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya Yamanaka in 2006, who demonstrated that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells. These cells possess the ability to develop into almost any type of cell within the human body, akin to embryonic stem cells, but without the associated ethical issues since they do not require the use of embryos. This groundbreaking discovery has opened up new avenues in regenerative medicine, drug discovery, and disease modeling. iPSCs are particularly promising for the development of patient-specific therapies where cells derived from the patients themselves can be used to treat a variety of conditions, from spinal cord injuries to Parkinson’s disease, potentially revolutionizing personalized medicine.

How Are iPSCs Revolutionizing Medical Research and Treatment?

The versatility of iPSCs has made them a valuable tool in the field of medical research and treatment. By reprogramming cells from patients with specific genetic disorders, scientists can create iPSCs that contain the same genetic anomalies. These iPSCs can then be used to study the pathology of diseases at a cellular level, providing insights that are not possible with other types of cells. For instance, iPSCs have been used to model diseases such as ALS, diabetes, and Alzheimer’s, allowing researchers to understand disease mechanisms and discover potential drug targets. Moreover, in the realm of drug testing, iPSCs can be used to evaluate the efficacy and safety of new pharmaceuticals before they are tested in humans, reducing the reliance on animal testing and improving the predictability of drug responses. These applications not only enhance our understanding of complex diseases but also pave the way for more effective and safer treatments.

What Technological Advancements Are Propelling iPSC Research?

Advancements in gene editing and tissue engineering are propelling the research and applications of iPSCs. The integration of CRISPR/Cas9 technology with iPSC technology has enabled precise alterations at the genetic level, enhancing the potential of iPSCs in therapeutic development and disease modeling. Researchers can now correct genetic defects in iPSCs derived from patients, potentially leading to cell therapy solutions that could cure inherited diseases. Additionally, the development of 3D bioprinting technologies allows for the construction of complex tissues from iPSCs, which could one day lead to the creation of organs for transplant. These technological innovations are crucial for overcoming current limitations in iPSC research, such as the efficiency of cell reprogramming and the maturity of differentiated cells, making these cells more viable for clinical applications.

What Drives the Rapid Expansion of the iPSC Market?

The growth in the iPSC market is driven by several factors, including significant advancements in biomedical research and an increasing emphasis on personalized medicine. The potential of iPSCs to provide patient-specific cells for therapy and research has led to substantial investment from both public and private sectors. The expansion of regenerative medicine, seeking to restore or establish normal function by replacing damaged cells, tissues, or organs, heavily relies on innovations in iPSC technology. Moreover, the growing prevalence of chronic diseases and genetic disorders increases the demand for novel treatment strategies that iPSCs could fulfill. Additionally, regulatory support and ethical acceptance of iPSCs compared to embryonic stem cells encourage further development and application of this technology. These drivers collectively foster a dynamic and rapidly advancing market, promising to revolutionize healthcare and treatment paradigms in the coming years.

SCOPE OF STUDY:

The report analyzes the Induced Pluripotent Stem Cell (iPSC) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Cell Type (Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells, Other Cell Types); Research Method (Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering, Other Research Methods); Application (Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine, Other Applications)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 51 Featured) -

  • Lonza Group Ltd.
  • Evotec SE
  • FUJIFILM Holdings Corporation
  • Abcam PLC
  • Horizon Discovery Ltd.
  • Cell Signaling Technology, Inc.
  • Cell Applications, Inc.
  • Invivogen
  • ALSTEM, LLC
  • Censo Biotechnologies Ltd.
  • Creative Bioarray
  • Creative Biolabs
  • Axol Bioscience Ltd.
  • ID Pharma Co., Ltd.
  • BlueRock Therapeutics, LLC

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Stem Cells, Application Areas, and the Different Types: A Prelude
    • Applications of Stem Cells
    • Types of Stem Cells
    • Induced Pluripotent Stem Cell (iPSC): An Introduction
    • Production of iPSCs
    • First & Second Generation Mouse iPSCs
    • Human iPSCs
    • Key Properties of iPSCs
    • Transcription Factors Involved in Generation of iPSCs
    • Noteworthy Research & Application Areas for iPSCs
    • Induced Pluripotent Stem Cell ((iPSC) Market: Growth Prospects and Outlook
    • Drug Development Application to Witness Considerable Growth
    • Technical Breakthroughs, Advances & Clinical Trials to Spur Growth of iPSC Market
    • North America Dominates Global iPSC Market
    • Competition
    • Recent Market Activity
    • Select Innovation/Advancement
    • Induced Pluripotent Stem Cell (iPSC) - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Effective Research Programs Hold Key in Roll Out of Advanced iPSC Treatments
    • Induced Pluripotent Stem Cells: A Giant Leap in the Therapeutic Applications
    • Research Trends in Induced Pluripotent Stem Cell Space
    • Concerns Related to Embryonic Stem Cells Shift the Focus onto iPSCs
    • Regenerative Medicine: A Promising Application of iPSCs
    • Induced Pluripotent: A Potential Competitor to hESCs?
    • Global Regenerative Medicine Market Size in US$ Billion for 2019, 2021, 2023 and 2025
    • Pluripotent Stem Cells Hold Significance for Cardiovascular Regenerative Medicine
    • Leading Causes of Mortality for Low-Income and High-Income Countries
    • Growing Importance of iPSCs in Personalized Drug Discovery
    • Persistent Advancements in Genetics Space and Subsequent Growth in Precision Medicine Augur Well for iPSCs Market
    • Global Precision Medicine Market (In US$ Billion) for the Years 2018, 2021 & 2024
    • Increasing Prevalence of Chronic Disorders Supports Growth of iPSCs Market
    • Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040
    • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Rising Diabetes Prevalence Presents Opportunity for iPSCs Market: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
    • Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for iPSCs Market
    • Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
    • Growth in Number of Genomics Projects Propels Market Growth
    • Genomic Initiatives in Select Countries
    • Launch of Numerous iPSCs-Related Clinical Trials Set to Benefit Market Growth
    • iPSCs-based Clinical Trial for Heart Diseases
    • Induced Pluripotent Stem Cells for Stroke Treatment
    • 'Off-the-shelf' Stem Cell Treatment for Cancer Enters Clinical Trial
    • iPSCs for Hematological Disorders
    • Market Benefits from Growing Funding for iPSCs-Related R&D Initiatives
    • Human iPSC Banks: A Review of Emerging Opportunities and Drawbacks
    • Human iPSC Banks Worldwide: An Overview
    • Cell Sources and Reprogramming Methods Used by Select iPSC Banks
    • Innovations, Research Studies & Advancements in iPSCs
    • Key iPSC Research Breakthroughs for Regenerative Medicine
    • Researchers Develop Novel Oncogene-Free and Virus-Free iPSC Production Method
    • Scientists Study Concerns of Genetic Mutations in iPSCs
    • iPSCs Hold Tremendous Potential in Transforming Research Efforts
    • Researchers Highlight Potential Use of iPSCs for Developing Novel Cancer Vaccines
    • Scientists Use Machine Learning to Improve Reliability of iPSC Self-Organization
    • STEMCELL Technologies Unveils mTeSR(TM) Plus
    • Challenges and Risks Related to Pluripotent Stem Cells
    • A Glance at Issues Related to Reprogramming of Adult Cells to iPSCs
    • A Note on Legal, Social and Ethical Considerations with iPSCs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Vascular Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Vascular Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Cardiac Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for Cardiac Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Neuronal Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for Neuronal Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Liver Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for Liver Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Immune Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for Immune Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Cell Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Other Cell Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Cellular Reprogramming by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for Cellular Reprogramming by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Cell Culture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 16: World 6-Year Perspective for Cell Culture by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Cell Differentiation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World 6-Year Perspective for Cell Differentiation by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Cell Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World 6-Year Perspective for Cell Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 21: World Recent Past, Current & Future Analysis for Cellular Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 22: World 6-Year Perspective for Cellular Engineering by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Research Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World 6-Year Perspective for Other Research Methods by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Drug Development & Toxicology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 26: World 6-Year Perspective for Drug Development & Toxicology Testing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 27: World Recent Past, Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 28: World 6-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Regenerative Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World 6-Year Perspective for Regenerative Medicine by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 32: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 33: World Induced Pluripotent Stem Cell (iPSC) Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 36: USA Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2025 & 2030
    • TABLE 40: USA Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: USA 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2025 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2025 & 2030
  • JAPAN
    • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2025 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2025 & 2030
  • CHINA
    • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 54: China Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2025 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2025 & 2030
  • EUROPE
    • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2025 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • FRANCE
    • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2025 & 2030
    • TABLE 70: France Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: France 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2025 & 2030
    • TABLE 72: France Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: France 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2025 & 2030
  • GERMANY
    • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2025 & 2030
    • TABLE 76: Germany Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Germany 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2025 & 2030
    • TABLE 78: Germany Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Germany 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2025 & 2030
    • TABLE 82: Italy Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Italy 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2025 & 2030
    • TABLE 84: Italy Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Italy 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2025 & 2030
    • TABLE 88: UK Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: UK 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2025 & 2030
    • TABLE 90: UK Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: UK 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2025 & 2030
    • TABLE 94: Rest of Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of Europe 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2025 & 2030
    • TABLE 96: Rest of Europe Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of Europe 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2025 & 2030
    • TABLE 100: Asia-Pacific Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Asia-Pacific 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2025 & 2030
    • TABLE 102: Asia-Pacific Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Asia-Pacific 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of World 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value Revenues for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2025 & 2030
    • TABLE 106: Rest of World Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Research Method - Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of World 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Research Method - Percentage Breakdown of Value Revenues for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for the Years 2025 & 2030
    • TABLE 108: Rest of World Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Application - Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Rest of World 6-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Application - Percentage Breakdown of Value Revenues for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Applications for the Years 2025 & 2030

IV. COMPETITION